TrialClinical cancer research : an official journal of the American Association for Cancer Research2023

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.

Chong Kin Liam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.